title: [Epidermal growth factor, innovation and safety].
abstract: Bioidentical recombinant human epidermal growth factor (rhEGF) is available in concentrations and purity suitable for therapeutic use in long time stable formulations. Beneficial effects in several skin pathologies and lesions have been reported (traumatic and surgical wound healing, laser induced wounds, abnormal scars, keloids, radiation or chemotherapy induced dermatitis, post inflammatory hyperpigmentation or for skin aging damage repairing) and also may be considered for the treatment of several oropharingeal and high gastroesophageal tract mucosa diseases (mouth sores, pharyngeal fistulas, ulcers), and several corneal or conjunctive mucosa lesions. rhEGF has not shown any important side or collateral effects in humans or in laboratory experimentation animals, showing optimal tolerability and safety with continuous use for months. Compounding gives advantages of versatility, individualization, personalization, molecular stability, safety and effectiveness in ideal conditions, showing good tissue penetration, both on intact skin and skin lesions that expose the lower planes to the surface. rhEGF compounds can be considered for prevention or as a treatment of diverse skin and mucosa diseases and conditions through compounding preparations.
authors.affiliation: Hospital Quirón Teknon, Barcelona, España; Servei Universitari de Recerca en Fisioteràpia (SURF), Escoles Universitàries Gimbernat, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: esquirol@dr.teknon.es.
authors.forename: Jordi
authors.initials: J
authors.lastname: Esquirol Caussa
authors.affiliation: Hospital Quirón Teknon, Barcelona, España; Servei de Medicina Preventiva, Àptima, Terrassa, Barcelona, España.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Herrero Vila
mesh_terms: D003879:Dermatologic Agents / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000627:therapeutic use*; D006801:Humans; D061214:Patient Safety; D011994:Recombinant Proteins / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy* / Q000517:prevention & control; D014947:Wounds and Injuries / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; D011994:Recombinant Proteins; D004815:Epidermal Growth Factor
keywords: Apósitos biológicos; Biological dressings; Crema para la piel; Cuidados de la piel; Enfermedades de la piel; Envejecimiento de la piel; Epidermal growth factor; Factor de crecimiento epidérmico; Pharmaceutical chemistry; Química farmacéutica; Skin aging; Skin care; Skin cream; Skin diseases